Literature DB >> 29907870

Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma.

Bart Hilvering1, Timothy S C Hinks1,2, Linda Stöger1, Emanuele Marchi3, Maryam Salimi4, Rahul Shrimanker1, Wei Liu1, Wentao Chen1, Jian Luo1, Simei Go1, Timothy Powell1, Jennifer Cane1, Samantha Thulborn1, Ayako Kurioka3, Tianqi Leng3, Jamie Matthews3, Clare Connolly1, Catherine Borg1, Mona Bafadhel1, Christian B Willberg3, Adaikalavan Ramasamy5, Ratko Djukanović2,6, Graham Ogg4, Ian D Pavord1, Paul Klenerman3, Luzheng Xue7.   

Abstract

Human type-2 CD8+ T cells are a cell population with potentially important roles in allergic disease. We investigated this in the context of severe asthma with persistent airway eosinophilia-a phenotype associated with high exacerbation risk and responsiveness to type-2 cytokine-targeted therapies. In two independent cohorts we show that, in contrast to Th2 cells, type-2 cytokine-secreting CD8+CRTH2+ (Tc2) cells are enriched in blood and airways in severe eosinophilic asthma. Concentrations of prostaglandin D2 (PGD2) and cysteinyl leukotriene E4 (LTE4) are also increased in the airways of the same group of patients. In vitro PGD2 and LTE4 function synergistically to trigger Tc2 cell recruitment and activation in a TCR-independent manner. These lipids regulate diverse genes in Tc2 cells inducing type-2 cytokines and many other pro-inflammatory cytokines and chemokines, which could contribute to eosinophilia. These findings are consistent with an important innate-like role for human Tc2 cells in severe eosinophilic asthma and suggest a potential target for therapeutic intervention in this and other diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29907870      PMCID: PMC6448764          DOI: 10.1038/s41385-018-0049-9

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  53 in total

1.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

Authors:  Ruth H Green; Christopher E Brightling; Susan McKenna; Beverley Hargadon; Debbie Parker; Peter Bradding; Andrew J Wardlaw; Ian D Pavord
Journal:  Lancet       Date:  2002-11-30       Impact factor: 79.321

2.  Transfer of the enhancing effect of respiratory syncytial virus infection on subsequent allergic airway sensitization by T lymphocytes.

Authors:  J Schwarze; M Mäkelä; G Cieslewicz; A Dakhama; M Lahn; T Ikemura; A Joetham; E W Gelfand
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

3.  Activated, cytotoxic CD8(+) T lymphocytes contribute to the pathology of asthma death.

Authors:  S O'Sullivan; L Cormican; J L Faul; S Ichinohe; S L Johnston; C M Burke; L W Poulter
Journal:  Am J Respir Crit Care Med       Date:  2001-08-15       Impact factor: 21.405

4.  Increased interleukin-4, interleukin-5, and interferon-gamma in airway CD4+ and CD8+ T cells in atopic asthma.

Authors:  Sang-Heon Cho; Luminita A Stanciu; Stephen T Holgate; Sebastian L Johnston
Journal:  Am J Respir Crit Care Med       Date:  2004-10-22       Impact factor: 21.405

5.  CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease.

Authors:  L Cosmi; F Annunziato; K Nagata; S Romagnani
Journal:  Eur J Immunol       Date:  2000-10       Impact factor: 5.532

6.  Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production.

Authors:  Mee Rhan Kim; Raffi Manoukian; Richard Yeh; Scott M Silbiger; Dimitry M Danilenko; Sheila Scully; Jilin Sun; Margaret L DeRose; Marina Stolina; David Chang; Gwyneth Y Van; Kristie Clarkin; Hung Q Nguyen; Yan Bin Yu; Shuqian Jing; Giorgio Senaldi; Gary Elliott; Eugene S Medlock
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

7.  Effector CD8+ T cells mediate inflammation and airway hyper-responsiveness.

Authors:  Nobuaki Miyahara; Bradley J Swanson; Katsuyuki Takeda; Christian Taube; Satoko Miyahara; Taku Kodama; Azzeddine Dakhama; Vanessa L Ott; Erwin W Gelfand
Journal:  Nat Med       Date:  2004-07-18       Impact factor: 53.440

Review 8.  A role for eosinophils in airway remodelling in asthma.

Authors:  A Barry Kay; Simon Phipps; Douglas S Robinson
Journal:  Trends Immunol       Date:  2004-09       Impact factor: 16.687

9.  Contribution of eotaxin-1 to eosinophil chemotactic activity of moderate and severe asthmatic sputum.

Authors:  Gordon Dent; Chrystalleni Hadjicharalambous; Takahiro Yoshikawa; Rachel L C Handy; John Powell; Ian K Anderson; Renaud Louis; Donna E Davies; Ratko Djukanovic
Journal:  Am J Respir Crit Care Med       Date:  2004-03-04       Impact factor: 21.405

10.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma.

Authors:  D S Robinson; Q Hamid; S Ying; A Tsicopoulos; J Barkans; A M Bentley; C Corrigan; S R Durham; A B Kay
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

View more
  16 in total

Review 1.  CD8+ Tc2 cells: underappreciated contributors to severe asthma.

Authors:  Timothy S C Hinks; Ryan D Hoyle; Erwin W Gelfand
Journal:  Eur Respir Rev       Date:  2019-11-20

Review 2.  Recent advances on the role of cytotoxic T lymphocytes in the pathogenesis of spondyloarthritis.

Authors:  Michael Tang; Robert D Inman
Journal:  Semin Immunopathol       Date:  2021-02-19       Impact factor: 11.759

3.  Large-scale provocation studies identify maladaptive responses to ubiquitous aeroallergens as a correlate of severe allergic rhinoconjunctivitis and asthma.

Authors:  Alisha M Smith; Robert M Ramirez; Nathan Harper; Fabio Jimenez; Anne P Branum; Justin A Meunier; Lavanya Pandranki; Andrew Carrillo; Caitlyn Winter; Lauryn Winter; Cynthia G Rather; Daniel A Ramirez; Charles P Andrews; Marcos I Restrepo; Diego J Maselli; Jacqueline A Pugh; Robert A Clark; Grace C Lee; Alvaro G Moreira; Muthu Saravanan Manoharan; Jason F Okulicz; Robert L Jacobs; Sunil K Ahuja
Journal:  Allergy       Date:  2021-10-22       Impact factor: 14.710

Review 4.  Non-eosinophilic asthma: current perspectives.

Authors:  Ignacio Esteban-Gorgojo; Darío Antolín-Amérigo; Javier Domínguez-Ortega; Santiago Quirce
Journal:  J Asthma Allergy       Date:  2018-10-29

5.  The predictive value of serum lipids for eye metastases in male nasopharyngeal carcinoma patients.

Authors:  Zhen Xie; Yi Shao
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

6.  The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D2 Production Are Attenuated by PGD2 Receptor 2 Antagonism.

Authors:  Wentao Chen; Jian Luo; Yuan Ye; Ryan Hoyle; Wei Liu; Rowie Borst; Shamsah Kazani; Eric A Shikatani; Veit J Erpenbeck; Ian D Pavord; Paul Klenerman; David A Sandham; Luzheng Xue
Journal:  J Immunol       Date:  2021-05-19       Impact factor: 5.422

Review 7.  T cells in severe childhood asthma.

Authors:  Alberta G A Paul; Lyndsey M Muehling; Jacob D Eccles; Judith A Woodfolk
Journal:  Clin Exp Allergy       Date:  2019-04-04       Impact factor: 5.018

Review 8.  The Biology of Prostaglandins and Their Role as a Target for Allergic Airway Disease Therapy.

Authors:  Kijeong Lee; Sang Hag Lee; Tae Hoon Kim
Journal:  Int J Mol Sci       Date:  2020-03-08       Impact factor: 5.923

9.  OMIP-062: A 14-Color, 16-Antibody Panel for Immunophenotyping Human Innate Lymphoid, Myeloid and T Cells in Small Volumes of Whole Blood and Pediatric Airway Samples.

Authors:  Dawid Swieboda; Yanping Guo; Sophie Sagawe; Ryan S Thwaites; Simon Nadel; Peter J M Openshaw; Fiona J Culley
Journal:  Cytometry A       Date:  2019-10-21       Impact factor: 4.355

10.  A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma.

Authors:  Hector Ortega; Mary Fitzgerald; Kartik Raghupathi; Cindy-Ann Tompkins; Jinshan Shen; Karen Dittrich; Caroline Pattwell; Dave Singh
Journal:  Clin Exp Allergy       Date:  2019-11-26       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.